Feasibility study of neoadjuvant gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer
Not Applicable
- Conditions
- Borderline resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000023591
- Lead Sponsor
- Kyorin University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) With pulmonary fibrosis or interstitial pneumonia 2) With active double cancers 3) With severe complications such as heart failure, bowel obstruction and uncontrollable diabetes millitus 4) With active infection 5) Pregnant or lactating women or women of childbearing potential and men who want to get partner pregnant 6) Psychosis or severe mental disorder 7) Recieving systemic steroid therapy 8) With severe drug allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Feasibility for 2 cycles of GEM+nab-PTX therapy
- Secondary Outcome Measures
Name Time Method R0 resection rate, Response rate, Histological effect, Adverse events, Severe adverse events, Treatment-related death